Leukemia is a cancer that’s unusual in that it begins in the bone marrow and invades the blood. The most prominent treatment options – drugs called tyrosine kinase inhibitors – have allowed for a 95 percent survival rate over the past five years and also allow leukemia patients to lead relatively normal lives.
"Fortunately, the problems we are studying affect a minority of chronic myeloid leukemia patients, but still, this leaves some patients with no good treatment option at all," said lead author and University of Utah life science researcher Dr. Thomas O'Hare. "Our goal is to have a tyrosine kinase inhibitor option for every patient."
Read More
Tags:
2014,
Utah,
UUtah,
cancer research,
UT,
University of Utah Salt Lake City
It’s not an uncommon dream for cancer researchers and patients afflicted with cancer to find a way to make cancer cells self-destruct: Remarkably, cancer researchers at the University of Texas, Austin may have found a way to do just that. By ferrying sodium and chloride ions into the cancer cells, the cells are triggered to go through apoptosis, or a programmed cell death.
Read More
Tags:
2014,
University of Texas,
cancer research,
Southwest,
UTAust,
Austin,
BioResearch Product Faire Event,
1 day only,
TX,
cancer researchers
The $500,000 Keck Fund research award was given earlier this year to bioengineering professors Kumar and Murthy for their project, Single Tumor Cell Proteomics for Diagnosis and Prognosis.
Tags:
2014,
University of California Berkeley,
proteomics,
cancer research,
BioResearch Product Faire Event,
UC Berkeley,
UCBerk
UCLA researchers have developed an innovative approach to diagnosing cancer. This research has excellent commercial applications and is already in the process of being translated into a novel technology by a Los Angeles start up. The new technique allows researchers to very accurately diagnose cancers by observing the physical characteristics of cells in bodily fluids.
Tags:
2014,
University of California Los Angeles,
cancer research,
Southwest,
California,
Los Angeles,
Cytometry,
LAVS,
BioResearch Product Faire Event,
UCLA
University of California life science researchers at the Jonsson Comprehensive Cancer Center have recently developed a novel and innovative cancer therapy approach that uses nanotechnology to fight brain cancer. This new technology uses nanotechnology structures called “nanodiamonds” to deliver chemotherapy agents directly to the cancerous areas in brain cancer patients.
Tags:
2014,
CA,
University of California Los Angeles,
2013,
cancer research,
nanotechnology,
Southwest,
California,
Los Angeles,
LAVS,
UCLA,
Biotechnology Vendor Showcase
Researchers at Stony Brook University recently received $1.2 million in life science funding from the NIH for a Sphingolipids in Cancer Biology and Therapy project led by Yusuf Awni Hannun. According to Stony Brook University, Dr. Hanuun is a renowned molecular biologist and physician-researcher interested in the molecular mechanisms of cancer. In 2012, he was appointed director of the Stony Brook Cancer Center, and he also serves as the Joel Kenny Professor of Medicine and Vice Dean for Cancer Medicine. The NIH RePORTER gives some background information on the project receiving NIH life science research funding:
Tags:
2014,
2013,
Northeast,
cancer research,
New York,
Stony Brook University,
BioResearch Product Faire Event,
NY,
NIH funding,
NIH grant,
NIH award,
Stony Brook,
SunySB
Researchers at Duke University recently made a groundbreaking contribution to the life sciences research field: The Duke researchers found that using certain bone grafting material for spinal fusion only sometimes increases the risk for benign tumors, and it does not increase the risk for cancer. Benign tumors were more common in patients who received the bone promoter recombinant human bone morphogenetic protein 2, also known as BMP.
Read More
Tags:
2014,
2013,
Duke University,
cancer research,
Southern,
BioResearch Product Faire Event,
Durham,
NC,
Duke,
research news
Researchers at Stony Brook University in collaboration with colleagues at Johns Hopkins School of Medicine used DNA sequencing methods to make a new discovery: the direct causation of exposure to aristolochic acid (AA), which is found in a plant that’s been used in herbal remedies for thousands of years, in the development of urothelial cancer.
Tags:
2014,
2013,
Northeast,
cancer research,
DNA Sequencing,
New York,
Stony Brook University,
BioResearch Product Faire Event,
NY,
Stony Brook,
research news,
SunySB
A new study by science researchers at Fred Hutchinson Cancer Research Center found that a number of lifestyle changes may be able to reduce the risk of or manage esophageal cancer. People who don’t smoke, keep their weight down, get regular exercise, eat a diet rich in fruits and vegetables, don’t eat four hours before they go to sleep, and avoid foods and beverages that give you heartburn (including caffeine, alcohol, chocolate, peppermint, onions, green peppers and foods that are high in fat) have a greatly reduced risk of getting esophageal cancer. Another Fred Hutchinson study found that cholesterol-reducing drugs are also associated with reduced risk.
Tags:
2014,
2013,
Fred Hutchinson Cancer Research Center,
Washington,
Medical Research,
WA,
Northwest,
cancer research,
WA research,
Washington Life Science,
Cancer Treatment,
BioResearch Product Faire Event,
Seattle,
research science information,
Hutch,
Cancer Center
In what is being hailed as a victory for both scientific research and patients' rights, the Supreme Court ruled unanimously yesterday that human genetic material cannot be patented. The case, Association for Molecular Pathology v. Myriad Genetics, has been working its way through the court system for a number of years now, led by plaintiffs including the ACLU, the American College of Medical Genetics, the American Society for Clinical Pathology, and numerous prominent genetic research scientists. The verdict invalidates the patents Myriad Genetics has held on breast cancer genes BRCA1 and BRCA2 since the 1990's and allows other labs besides theirs to test for mutations in those genes which, when present, strongly indicate a genetic predisposition to cancer. It also means that scientists can move forward in their genetic research without threat of being sued for copyright infringement. While the case was brought against Myriad specifically, the decision to disallow human gene patenting has profound implications for both scientific discovery and individual rights of ownership over our own genetic material.
Read More
Tags:
2014,
CA,
2013,
Bioresearch,
gene patenting,
cancer research,
Southwest,
Southwest life science marketing events,
Cancer Treatment,
San Diego,
SDVS,
Genetics,
UC San Diego,
biotech industry,
Biotechnology Vendor Showcase
